July 2017, Volume 3, Issue 8
This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.
June 2017, Volume 3, Issue 7
This issue features a look at NIH's new data-sharing requirements, Mikkael Sekeres' thoughts on contract research organizations, and more.
May 2017, Volume 3, Issue 6
This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.
May 2017 Special Edition
This special edition features updates in the world of myeloid malignancies, including a review of investigational treatment options and news from recent hematologic conferences.
April 2017, Volume 3, Issue 5
This issue examines the art and science of myeloma drug sequencing, Mikkael Sekeres' letter to the ABIM, highlights from the 16th International Myeloma Workshop, and more.
March 2017, Volume 3, Issue 4
This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.
February 2017, Volume 3, Issue 3
This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.
January 2017 Annual Meeting Edition
This issue features expanded coverage of the 2016 ASH Annual Meeting, as well as a focus on CAR T-cell therapy, and more.
January 2017, Volume 3, Issue 1
This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.
December 2016, Volume 2, Issue 12
This issue features a look at the 2016 ASH Mentor Awards, a preview of the ASH Annual Meeting, the challenges of designing a clinical trial that is both internally and externally valid, and more.
Current Issue
July 2017, Volume 3, Issue 8
This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.
